Summary
This 8-K filing from Merck & Co., Inc. (MRK), filed on June 3, 2003, primarily addresses regulatory matters and investor communication strategies. A key development is the FDA's concurrence with Schering-Plough Corporation’s CGMP Work Plans related to a Consent Decree. While the filing is from Merck, it references Schering-Plough's regulatory issues, indicating potential strategic or operational connections, though the exact nature is not detailed in this excerpt. Investors should note that information regarding Schering-Plough's CGMP Work Plans and the Consent Decree can be found in Schering-Plough's own SEC filings, including their first quarter 2003 10-Q. Furthermore, the filing outlines Merck's approach to disseminating international press releases concerning drug approvals in other countries that are not yet approved in the U.S. To comply with U.S. FDA regulations, these releases will be posted on Merck's Investor Relations Web Site rather than being issued directly in the U.S. This ensures investors have access to potentially relevant global market information. The company also offers an e-mail alert service for investors to stay updated on all press releases posted to their website.
Key Highlights
- 1FDA has concurred with Schering-Plough Corporation's CGMP Work Plans related to a Consent Decree.
- 2Details regarding Schering-Plough's CGMP Work Plans and Consent Decree are available in Schering-Plough's SEC filings.
- 3Merck will post international press releases (regarding drug approvals outside the U.S.) on its Investor Relations Web Site.
- 4This practice is to comply with U.S. FDA regulations concerning press releases for unapproved drugs/uses in the U.S.
- 5Investors can sign up for e-mail alerts on the Investor Relations Web Site for all press release postings.
- 6An exhibit containing Frequently Asked Questions (FAQs) for investors is filed with this 8-K.
- 7The FAQs will also be posted on the Investor Relations Web Site.